T5.12 Kilder
Bipolar lidelse
Yatham LN, Kennedy SH, Parikh SV, et. al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14. PMID: 29536616; PMCID: PMC5947163.
Søvnvansker
Bjorvatn B, Pallesen S. A practical approach to circadian rhythm sleep disorders. Sleep Medicine Reviews, 2009; 13: 47-60.
Bjorvatn B, Fiske E, Pallesen S. A self-help book is better than sleep hygiene advice for insomnia. A randomized controlled comparative study. Scand J Psychology 2011; 52: 580-585.
Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc L, Espie CA, Garcia-Borreguero D, Gjerstad M, Goncalves M, Hertenstein E, Jansson-Fröjmark M, Jennum PJ, Leger D, Nissen C, Parrino L, Paunio T, Pevernagie D, Weess H-G, Wichniak A, Zavalko I, Spiegelhalder K. European guideline for the diagnosis and treatment of insomnia. J Sleep Research 2017; 26: 675-700.
https://www.helsedirektoratet.no/veiledere/vanedannende-legemidler
https://www.uptodate.com/contents/behavioral-and-pharmacologic-therapies-for-chronic-insomnia-in-adults
www.sovno.no
Bjorvatn B, Sivertsen B, Waage S, Holsten F, Pallesen S. Nasjonal anbefaling for utredning og behandling av insomni. SØVN 2018; 10(1): 12-17.
Bjorvatn B, Kallestad H, Langsrud K, Vedaa Ø, Pallesen S, Waage S, Wilhelmsen-Langeland A, Saxvig IW, Abeler K. Nasjonal anbefaling for utredning og behandling av døgnrytmelidelser. SØVN 2023; 15(1): 32-50.
St‐Onge M, Grandner MA, Brown D, et al. Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health: a scientific statement from the American Heart Association. Circulation. 2016; 134:e367–e386. doi: 10.1161/CIR.0000000000000444
Huang T, Mariani S, Redline S. Sleep irregularity and risk of cardiovascular events: the Multi‐Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2020; 75:991–999. doi: 10.1016/j.jacc.2019.12.054
Makarem N, St‐Onge M, Liao M, Lloyd‐Jones DM, Aggarwal B. Association of sleep characteristics with cardiovascular health among women and differences by race/ethnicity and menopausal status: findings from the American Heart Association Go Red for Women Strategically Focused Research Network. Sleep Health. 2019; 5:501–508. doi: 10.1016/j.sleh.2019.05.005
Makarem N, Castro-Diehl C, St-Onge MP, et al. Redefining Cardiovascular Health to Include Sleep: Prospective Associations With Cardiovascular Disease in the MESA Sleep Study published online ahead of print, 2022 Oct 19. J Am Heart Assoc. 2022;e025252. doi:10.1161/JAHA.122.025252
Lloyd-Jones DM et al. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Ciculation 2022; 146 (5): :e18–e43 doi.org/10.1161/CIR.0000000000001078
Rusproblemer og avhengighetstilstander
Bramness JG, Rognli EB, Andreassen OA. Kapittel 13, Rusmidler og avhengighet. I Andreassen OA, Malt UF, Malt EA, Melle I (red) Lærebok i psykiatri Oslo 2020 Gyldendal
Bramness, JG, Hva er avhengighet. Oslo 2018, Universitetsforlaget
Bramness JG, Vøyvik T. Rasjonell bruk av angst og sovemedisiner, Oslo 2017, Universitetsforlaget
Bretteville-Jensen AL, Bramness JG. Cannabisboka, Oslo 2019, Universitetsforlaget
Helsedirektoratet. Motiverende intervju som metode (https://www.helsedirektoratet.no/tema/motiverende-intervju-mi/motiverende-intervju-som-metode)
Helsedirektoratet Nasjonal veileder vanedannende medisiner (https://www.helsedirektoratet.no/veiledere/vanedannende-legemidler)
Fredheim OM, Nøstdahl T, Nordstrand B, Høivik T, Rygnestad T, Borchgrevink PC. Behandling av akutte smerter under legemiddelassistert rehabilitering. Tidsskr Nor Laegeforen. 2010;130(7):738-40.
Nishimoto A, Usery J, Winton JC, Twilla J. High-dose Parenteral Thiamine in Treatment of Wernicke's Encephalopathy: Case Series and Review of the Literature. In Vivo. 2017;31(1):121-4.
Eline Borger Rognli, Sigrid Elisabet Medhus, Jørgen G. Bramness. Amfetaminutløst psykose eller schizofreni? Tidsskr Nor Legeforen 2015; 135: 249-51 doi: 10.4045/tidsskr.14.1365
Cannabis og psykose
Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011; 342: d738. doi: 10.1136/bmj.d738.
Feiring E. Hasj kan gi psykoser. TnLF 2005; 125: 10.
Bretteville-Jensen AL (red). Hva vet vi om cannabis? Universitetsforlaget 2012, Oslo
Andréasson S1, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987 Dec 26; 2(8574): 1483-6.
Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ : British Medical Journal 2002; 325(7374): 1212-1213.
Gage SH, Hickman M, Zammit S. Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biol Psychiatry 2015 Aug 12. pii: S0006-3223(15)00647-2. doi: 10.1016/j.biopsych.2015.08.001.
Nesvåg R, Reichborn-Kjennerud T, Gillespie NA, Knudsen GP, Bramness JG, Kendler KS, Ystrom E. Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins. Schizophrenia Bulletin, Volume 43, Issue 3, 1 May 2017, Pages 644–653, https://doi.org/10.1093/schbul/sbw101
Delirium
Marcantonio ER. Delirium in Hospitalized Older Adults. The New England journal of medicine. 2017;377(15):1456-66.
Nikooie R, Neufeld KJ, Oh ES, Wilson LM, Zhang A, Robinson KA, et al. Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review. Ann Intern Med. 2019.
Oh ES, Needham DM, Nikooie R, Wilson LM, Zhang A, Robinson KA, et al. Antipsychotics for Preventing Delirium in Hospitalized Adults: A Systematic Review. Ann Intern Med. 2019.
Reznik ME, Slooter AJC. Delirium Management in the ICU. Current treatment options in neurology. 2019;21(11):59.
https://www.sign.ac.uk/sign-157-delirium.html
https://www.cochrane.org/CD005594/DEMENTIA_antipsychotics-treat-delirium-hospitalised-patients-not-including-those-intensive-care-units
https://www.cochrane.org/CD011749/EMERG_medicines-treat-delirium-critically-ill-adult-patients
Demens
Helsedirektoratet. Nasjonal faglig retningslinje om demens Utgitt: 18.08.2017 IS-2658 sist oppdatert 03.januar 2020. https://helsedirektoratet.no/retningslinjer/nasjonal-faglig-retningslinje-om-demens
Nasjonal kompetansetjeneste for aldring og helse. https://www.aldringoghelse.no/demens
Birks J. Cholinesterase inhibitors for Alzheimer's disease. The Cochrane database of systematic reviews. 2006(1):Cd005593.
WHO Guidelines Approved by the Guidelines Review Committee. Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines. Geneva: World Health Organization 2019. https://www.who.int/mental_health/neurology/dementia/guidelines_risk_reduction/en/
Knapskog A-B, Engedal K, Selbæk G, Øksengård A-R. Alzheimers sykdom – diagnostikk og behandling. Tidsskr Nor Legeforen 2021 doi: 10.4045/tidsskr.20.0919.
Depresjoner
Andreassen, Malt, Malt, Melle. Lærebok i psykiatri, basisversjon, Gyldendal, 2020
Nationella riktlinjer för vård vid depression och ångestsyndrom. Socialstyrelsen, 2020.
Goodwin&Jamison. Manic Depressive Illness, Second Edition, Oxford 2007
Westergren T,
Narum S, Klemp M. Critical
appraisal of adverse effects
reporting in the ‘Treatment for
Adolescents With Depression
Study (TADS)’. BMJ Open
2019;9:e026089. doi:10.1136/
bmjopen-2018-026089
Solhaug V, Haslemo T, Kringen MK, Molden E, Dietrichs ES. Genotyping of patients treated with selective serotonin reuptake inhibitors. Tidsskr Nor Laegeforen. 2022 Sep 26;142(13). English, Norwegian. doi: 10.4045/tidsskr.22.0017. PMID: 36164782.
Hyperkinetiske forstyrrelser
ADHD/hyperkinetisk forstyrrelse – nasjonal faglig retningslinje for utredning, behandling og oppfølging. Rett diagnose – individuell behandling. Helsedirektoratet Desember 2014 Bestillingsnummer: IS-2060 ISBN-nr. 978-82-8081-283-4 https://www.helsedirektoratet.no/retningslinjer/adhd American
Academy of Child and Adolescent Psychiatry (2007): Practice Parameters for the Assessment and Treatment of Attention-Deficit Hyperactivity Disorder https://www.jaacap.org/article/S0890-8567(09)64587-1/fulltext American
Academy of Child and Adolescent Psychiatry (2009):Practice Parameter on the Use of Psychotropic Medication in Children and Adolescents. https://jaacap.org/article/S0890-8567(09)60156-8/fulltext
American Academy of Pediatrics, ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and AdolescentsDisorder (2011) https://pediatrics.aappublications.org/content/128/5/1007
National Institute for Health and Clinical Excellence – ADHD, oppdatert 2018. https://www.nice.org.uk/guidance/ng87
Norsk barne- og ungdomspsykiatrisk forening. Veileder i BUP (2016). Hyperkeinetiske forstyrrelser ved Zeiner P., Weidle B. https://legeforeningen.no/Fagmed/Norsk-barne--og-ungdomspsykiatrisk-forening/Faglig-veileder-for-barne-og-ungdomsspsykiatri/Del-2/f-90-hyperkinetiske-forstyrrelser/
Norsk barnelegeforening. Generell veileder. Nevrologi. (2010). AD/HD/Hyperkinetiske forstyrrelser. https://www.helsebiblioteket.no/pediatriveiledere?menuitemkeylev1=5962&menuitemkeylev2=5973&key=144650
Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE. (2012). A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012 Sep 4;10:99. doi: 10.1186/1741-7015-10-99. https://www.ncbi.nlm.nih.gov/pubmed/22947230
Taylor E. et al. (2004). European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry [Suppl 1] 13:I/7–I/30 (2004) DOI 10.1007/s00787-004-1002-x. http://dare.ubvu.vu.nl/bitstream/handle/1871/18265/Taylor_European?sequence=2
Tourettes syndrom
Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 2011; 20(4): 173-96.
Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry 2012; 57(3): 133-43.
Scahill L, Erenberg G, Berlin CM, Jr., Budman C, Coffey BJ, Jankovic J et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006; 3(2): 192-206.
Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez A. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry 1993; 32(2): 350-3.
Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J. Clin Psychiatry 2001; 62(1): 50-6.
Budman C, Coffey BJ, Shechter R, Schrock M, Wieland N, Spirgel A et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008; 18(5): 509-15.
Srour M, Lespérance P, Richer F, Chouinard S. Psychopharmacology of tic disorders. J Can Acad Child Adolesc Psychiatry 2008; 17(3): 150-9.
Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010; 81(1): 70-3.
Martínez-Granero MA, García-Pérez A, Montañes F. Levetiracetam as an alternative therapy for Tourette syndrome. Neuropsychiatr Dis Treat. 2010; 6: 309-16.
Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48(9):884-93.
Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol. 2012;47(2):77-90.
Pozzi M, Pisano S, Marano G, Carnovale C, Bravaccio C, Rafaniello C, Capuano A, Rossi F, Rizzo R, Bernardini R, Nobile M, Molteni M, Clementi E, Biganzoli E, Radice S. Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. J Child Adolesc Psychopharmacol. 2019;29(2):133-140.Pringsheim T, Okun MS, Müller-Vahl K, Martino D, Jankovic J, Cavanna AE, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M, Holler-Managan Y, Piacentini J. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896-906.
Yang C, Hao Z, Zhu C, Guo Q, Mu D, Zhang L. Interventions for tic disorders: An overview of systematic reviews and meta analyses. Neurosci Biobehav Rev. 2016;63:239-55.
Wernickes encefalopati
Nishimoto A, Usery J, Winton JC, Twilla J. High-dose Parenteral Thiamine in Treatment of Wernicke's Encephalopathy: Case Series and Review of the Literature. In Vivo. 2017 Jan 2;31(1):121-124. doi: 10.21873/invivo.11034. PMID: 28064230; PMCID: PMC5354137.